Insmed reported $3.22B in Market Capitalization for its second fiscal quarter of 2021.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Market Capitalization Change
Acelrx Pharmaceuticals ACRX:US $ 164.36M 37.85M
Alexion Pharmaceuticals ALXN:US $ 33.78B 393.15M
Alimera Sciences ALIM:US $ 62.78M 7.43M
Arena Pharmaceuticals ARNA:US $ 4.16B 41.38M
Biomarin Pharmaceutical BMRN:US $ 15.25B 1.45B
Cytokinetics CYTK:US $ 1.42B 244.24M
Dbv Technologies DBVT:US 550.75M 53.79M
Dynavax Technologies DVAX:US $ 1.13B 15.39M
Flexion Therapeutics FLXN:US $ 411.02M 35.8M
Gilead Sciences GILD:US $ 86.36B 4.99B
Heron Therapeutics HRTX:US $ 1.58B 98.85M
Insmed INSM:US $ 3.22B 293.47M
Mirati Therapeutics MRTX:US $ 8.31B 483.81M
Novartis NVS:US 203.48B 21.43B
Ophthotech OPHT:US $ 569.51M 12.26M
Regeneron Pharmaceuticals REGN:US $ 59.5B 8.81B
Sarepta Therapeutics SRPT:US $ 6.2B 282.45M
Seattle Genetics SGEN:US $ 28.65B 3.48B
Ultragenyx Pharmaceutical RARE:US $ 6.43B 1.19B
Vertex Pharmaceuticals VRTX:US $ 52.2B 3.42B